The End of Low-Hanging Fruit in Longevity Biotech скачать в хорошем качестве

The End of Low-Hanging Fruit in Longevity Biotech

In this visionary talk, Gero.ai’s co-founder challenges conventional longevity biotech thinking and makes a compelling case for the future of aging research. Instead of chasing incremental gains via the “hallmarks of aging,” Gero.ai uses large-scale human data, machine learning, and pharmaceutical partnerships to identify drug targets that could meaningfully extend both average and maximum lifespan. Backed by VitaDAO and engaged in real-world collaborations with major pharma companies, Gero.ai introduces a tiered framework for longevity interventions—from GLP-1-like effects to drugs that shift the mortality curve itself. This talk explores the failures of current mouse-based models, the trillion-dollar opportunity in extending healthy lifespan, and how AI-powered biology can unlock it.